Chapel Hill startup with ties to UNC lands rights to drug offering hope to cystic fibrosis patients

Posted Oct 27, 2019
Path BioAnalytics (PBA), a precision medicine startup with ties to UNC, has scored the rights to a new drug therapy offering hope to cystic fibrosis (CF) patients with rare mutations. PBA is a graduate of Launch Chapel Hill, an accelerator program based in Chapel Hill, as well as the Kenan Flagler Business School program Startup UNC. (WRAL Tech Wire)

Related: Campus Connections

Gift from UNC alums will fund 20 Carolina Covenant scholars
A transformational estate gift from Dwight Jacobs ’87 and Moira Jacobs ’87 will support future generations of Carolina Covenant scholars. “If we could help 20...
Mon Feb 9, 2026

Tar Heels revel in winter weather (again)
Coming off the heels of last weekend’s snow/sleet/ice mix, UNC received more wintry weather this weekend. This time Tar Heels had pure snow to enjoy...
Sun Feb 8, 2026

UNC alumna Dajah Stallings heads to the Super Bowl as member of Seattle Seahawks staff
You know about former UNC quarterback Drake Maye leading the New England Patriots to the Super Bowl. Serious fans might also be able to name...
Wed Feb 4, 2026

THT Newsletter: Caleb Wilson Comes Home, Belichick Denied, UNC Women's Tennis Takes Down No. 1
Since we last caught up, Caleb Wilson had a happy homecoming in Atlanta, Bill Belichick was denied election to the Pro Football Hall of Fame...
Mon Feb 2, 2026